Evidence-Based Reviews

Repetitive transcranial magnetic stimulation for tic disorders

Author and Disclosure Information

 

References

Safety profile and adverse effects. In the studies we reviewed, the adverse effects associated with rTMS included headache (45%),1,8,24,26,28,29 scalp pain (18%),8,30 self-injurious crisis (9%),31 abdominal pain (9%),29 red eyes (9%),29 neck pain (9%),1 muscle sprain (9%),1 tiredness (9%),24,26 and increase in motor excitability (9%).28 There were no severe adverse effects reported in any of the studies. The self-injurious crisis reported by a patient early in one study as a seizure was later ruled out after careful clinical and electroencephalographic evaluation. This patient demonstrated self-injurious behaviors prior to the treatment, and overall there was a reduction in frequency and intensity of self-injurious behavior as well as an improvement in tics.31

Dissimilar studies

There was great heterogeneity among the 11 studies we reviewed. One case series27 and one case report31 found significant improvement in tics, but these studies did not have control groups. Both studies employed rTMS with a frequency of 1 Hz and between 900 to 1,200 pulses per day. Three open-label studies that found significant improvement in tic severity used the same frequency of stimulation (1 Hz with 1,200 pulses per day).3,23,30 All studies we analyzed differed in the total number of rTMS sessions and number of trains per stimulation.

The studies also differed in terms of the age of the participants. Some studies focused primarily on pediatric patients,3,30 but many of them also included adults. The main limitations of the 11 studies included a small sample size,1,3,8,23-25,28-30 no placebo or controlled arm,1,3,8,23,27,30,31 concomitant psychiatric comorbidities8,28,29 or medications,1,3,23,29,30 low stimulation intensity,24-26 and use of short trains24,26 or unilateral cerebral stimulation.24,26 Among the blinded studies, limitations included a small sample size, prior medications used, comorbidities, low stimulation intensity, and high rTMS dose.1,24-26,28,29

A possible option for treatment-resistant tics

We cannot offer a definitive conclusion on the safety and effectiveness of rTMS for the treatment of TS and other tic disorders because of the inconsistent results, heterogeneity, and small sample sizes of the studies we analyzed. Higher-quality studies failed to find evidence supporting the use of rTMS for treating TS and other tics disorders, but open-label studies and case reports found significant improvements. In light of this evidence and the treatment’s relatively favorable adverse-effects profile, rTMS might be an option for certain patients with treatment-resistant tics, particularly those with comorbid OCD symptoms.

Continue to: Bottom Line

Pages

Recommended Reading

High-intensity treadmill workouts preserved motor function in early-stage Parkinson’s
MDedge Psychiatry
Gene silencer reduces mutant huntingtin protein in early-stage Huntington’s patients
MDedge Psychiatry
Corynebacterium in the gut can trigger Parkinson’s disease
MDedge Psychiatry
Low caffeine in blood could be marker of early Parkinson’s
MDedge Psychiatry
Mutations on LRRK2 gene modify risks for both Crohn’s and Parkinson’s
MDedge Psychiatry
MDedge Daily News: Could gut bacteria trigger lupus?
MDedge Psychiatry
Psychiatric subspecialty is changing its name
MDedge Psychiatry
VIDEO: Encouraging results reported for novel Huntington’s disease therapy
MDedge Psychiatry
Real-world data so far support pimavanserin trial results
MDedge Psychiatry
Anticholinergics’ link to dementia calls for vigilance in elderly
MDedge Psychiatry